Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦
@pabeda1
Cardiologist, Associate Prof. of Internal Medicine, Rio de Janeiro State University. Passion for preventive Cardiology, heart failure, art and classical music
#ESCCongress2025 Hot lines released! @escardio . Do we really need beta-blockers after MI in pts w/normal or mildly reduced EF? @Hragy @HanCardiomd @SABOURETCardio @DrMarthaGulati @mmamas1973 @fjpinto1960
👇👇👇 #Hypertension #aldosterone @AnastasiaSMihai @nicolasrennamd
Subclinical Primary Aldosteronism and MACE ahajournals.org/doi/10.1161/CI…
👇👇👇 Very interesting and available for free download, thanks @drpablocorral for sharing!
🤔If high LDL cholesterol is so dangerous… why doesn’t it hurt? ☝️Because evolution doesn’t care if you drop dead after you’ve reproduced. 👉LDL cholesterol is a silent killer—causal, cumulative, and completely asymptomatic. You won’t feel your arteries clogging. You won’t…
Great insights from @ProfKausikRay on the Victorian Mono study.
Our editorial of the Victorian Mono trial provides a nuanced understanding of the interplay between diet, LDLR- PCSK9 and circulating LDL-C levels through the Len’s of known knowns, known unknowns and unknown unknowns kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…
EHJ: DOI: 10.1093/eurheartj/ehaf210 DOI: 10.1093/eurheartj/ehaf174 DOI: 10.1093/eurheartj/ehaf266 2 meta analyses of colchicine in 2ary prevention of vascular events + editorial. Modest benefits, large NNT's, between-trial heterogeneity. Now what? #CardioTwitter #Cardiology
#ESCCongress2025 This is going to be really hot: #Hypertension trials w/#baxdrostat and #zilbesiran! @AnastasiaSMihai @AnandVaidya17 @AtulPathak31
#ESCCongress2025: Will #vericiguat have a role in chronic heart Failure? VICTOR study will be presented at Hot Line 2 (Did someone read a press release from Bayer? I didn't...). @HanCardiomd @mvaduganathan @hvanspall @SJGreene_md @SantosGallegoMD @luisbeckdasilva
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia merck.com/news/merck-ann…
Published today: ahajournals.org/doi/10.1161/CI… Alcohol and cardiovasculsr disease: There seem to be many gaps in knowledge regarding low/moderate consumption... #cardiovascular #hypertension @SABOURETCardio @SantosGallegoMD @Hragy @RajayNarain @DrRajivsankar @rladeiraslopes
📢 1 week to go – don’t miss out! Join Professor Pablo Corral and leading experts for the EAS Advanced Course on Rare Lipid Disorders: Bridging Knowledge and Clinical Practice in LatAm 🗓️ Date: 11 June 2025 🕓 Time: 16:00 ART 🌐 Language: Spanish ✅ Deep dive into genetics,…
Invitation from Professor Pablo Corral Join us for the upcoming EAS Advanced Course on Rare Lipid Disorders: Bridging Knowledge and Clinical Practice in LatAm 🗓️ Date: 11 June 2025 🕓 Time: 16:00 ART (Argentina Time) 🌐 This course will be delivered in Spanish 👨⚕️ Tailored for…
Invitation from Professor Pablo Corral Join us for the upcoming EAS Advanced Course on Rare Lipid Disorders: Bridging Knowledge and Clinical Practice in LatAm 🗓️ Date: 11 June 2025 🕓 Time: 16:00 ART (Argentina Time) 🌐 This course will be delivered in Spanish 👨⚕️ Tailored for…
Following #Heartfailure2025 tweets with this beautiful sunny sunday background in Copacabana! @novitskiynic @GiuseppeGalati_ @FH_Verbrugge @VerwerftJan @luisbeckdasilva
New @society_eas #AtheroTalk episode is out! In this episode, we talk with Prof. Noam Zelcer on the evolving field of lipid metabolism research, failures as a feature of science, defining priorities for projects. Looking for a position? This is also your episode! ⬇️Links below
🔥Summary of hottest trials, trial updates and registries by day in cards below #HeartFailure2025 @escardio @HFA_President @ShelleyZieroth @hvanspall @ARakisheva @GiuseppeGalati_ @mvaduganathan @corneliacrm @slumberbell @JBauersachsMD @areciomayoral @m4ggiesimpson
That was cool, my thanks to @society_eas !
What happens when science meets storytelling? At the EAS Stage, the SoMe Team explored how social media can amplify research, boost physician voices & spark real-time connections. 👉Social media isn’t just a tool — it’s part of the conversation.#EASCongress2025
The first human experience with MAR001, a drug targeting ANGPTL4, shows promising results. Phase 2a demonstrated a 50% red in TG and a sign lowering of RC. This could translate into a predicted 20-35% red in MACE, supported by human genetics and RC epidemiology #EASCongress2025